Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Palliative Care | 32 | 2023 | 2037 | 3.010 |
Why?
|
| Pain Management | 10 | 2021 | 668 | 2.020 |
Why?
|
| Cachexia | 9 | 2019 | 161 | 1.800 |
Why?
|
| Neoplasms | 46 | 2023 | 15193 | 1.730 |
Why?
|
| Terminal Care | 8 | 2017 | 447 | 1.460 |
Why?
|
| Pain | 9 | 2023 | 1658 | 1.440 |
Why?
|
| Analgesics, Opioid | 12 | 2023 | 1371 | 1.300 |
Why?
|
| Cancer Pain | 6 | 2021 | 312 | 1.020 |
Why?
|
| Dehydration | 4 | 2012 | 87 | 0.790 |
Why?
|
| Fluid Therapy | 4 | 2012 | 182 | 0.730 |
Why?
|
| Hypogonadism | 3 | 2019 | 257 | 0.730 |
Why?
|
| Ghrelin | 2 | 2019 | 79 | 0.730 |
Why?
|
| Pain Measurement | 6 | 2019 | 953 | 0.730 |
Why?
|
| Analgesics | 3 | 2018 | 390 | 0.690 |
Why?
|
| Lipid Metabolism | 2 | 2019 | 483 | 0.650 |
Why?
|
| Referral and Consultation | 5 | 2023 | 899 | 0.630 |
Why?
|
| Body Composition | 3 | 2019 | 595 | 0.580 |
Why?
|
| Cultural Competency | 1 | 2017 | 60 | 0.550 |
Why?
|
| Professional-Family Relations | 1 | 2017 | 134 | 0.540 |
Why?
|
| Communication | 3 | 2017 | 876 | 0.500 |
Why?
|
| Insulin Resistance | 1 | 2019 | 731 | 0.480 |
Why?
|
| Anorexia | 4 | 2021 | 143 | 0.470 |
Why?
|
| Informed Consent | 1 | 2017 | 419 | 0.460 |
Why?
|
| Names | 1 | 2013 | 6 | 0.460 |
Why?
|
| Verbal Behavior | 1 | 2013 | 62 | 0.440 |
Why?
|
| Delirium | 5 | 2020 | 207 | 0.430 |
Why?
|
| Precision Medicine | 3 | 2018 | 1154 | 0.400 |
Why?
|
| Terminally Ill | 1 | 2011 | 91 | 0.370 |
Why?
|
| Physician-Patient Relations | 2 | 2013 | 792 | 0.360 |
Why?
|
| Attitude of Health Personnel | 2 | 2015 | 918 | 0.360 |
Why?
|
| Advance Directives | 2 | 2013 | 88 | 0.340 |
Why?
|
| Strontium Radioisotopes | 1 | 2008 | 26 | 0.340 |
Why?
|
| Psychomotor Agitation | 2 | 2020 | 78 | 0.330 |
Why?
|
| Hypercalcemia | 1 | 2008 | 137 | 0.310 |
Why?
|
| Humans | 61 | 2023 | 261506 | 0.300 |
Why?
|
| Testosterone | 4 | 2019 | 619 | 0.300 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 761 | 0.290 |
Why?
|
| Hot Flashes | 1 | 2006 | 37 | 0.280 |
Why?
|
| Benzodiazepines | 2 | 2019 | 170 | 0.280 |
Why?
|
| Advance Care Planning | 3 | 2023 | 86 | 0.270 |
Why?
|
| Medical Oncology | 5 | 2021 | 1423 | 0.270 |
Why?
|
| Body Mass Index | 2 | 2015 | 2203 | 0.260 |
Why?
|
| Outpatients | 4 | 2023 | 462 | 0.250 |
Why?
|
| Comorbidity | 3 | 2019 | 2352 | 0.240 |
Why?
|
| Vomiting | 2 | 2021 | 354 | 0.240 |
Why?
|
| Nausea | 2 | 2021 | 525 | 0.230 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 1946 | 0.230 |
Why?
|
| Fever | 1 | 2006 | 497 | 0.220 |
Why?
|
| Haloperidol | 2 | 2020 | 64 | 0.220 |
Why?
|
| Neuroendocrine Tumors | 1 | 2008 | 634 | 0.210 |
Why?
|
| Drug Administration Routes | 2 | 2012 | 60 | 0.210 |
Why?
|
| Fentanyl | 2 | 2022 | 148 | 0.210 |
Why?
|
| Quality of Life | 8 | 2021 | 4532 | 0.210 |
Why?
|
| Celiac Plexus | 1 | 2021 | 13 | 0.200 |
Why?
|
| Oxymorphone | 1 | 2021 | 9 | 0.200 |
Why?
|
| Cancer Care Facilities | 3 | 2019 | 884 | 0.200 |
Why?
|
| Parenteral Nutrition | 2 | 2012 | 207 | 0.200 |
Why?
|
| Radiation Injuries | 1 | 2008 | 1411 | 0.190 |
Why?
|
| Dyspnea | 2 | 2019 | 416 | 0.190 |
Why?
|
| Patient Care Planning | 3 | 2023 | 297 | 0.190 |
Why?
|
| Middle Aged | 27 | 2021 | 86204 | 0.190 |
Why?
|
| Male | 31 | 2023 | 123000 | 0.190 |
Why?
|
| Cytokines | 3 | 2018 | 2809 | 0.190 |
Why?
|
| Substance Abuse Detection | 1 | 2020 | 64 | 0.190 |
Why?
|
| Antiemetics | 1 | 2021 | 125 | 0.190 |
Why?
|
| Acupuncture Therapy | 1 | 2021 | 89 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 2 | 2021 | 5061 | 0.180 |
Why?
|
| Hydrazines | 1 | 2021 | 208 | 0.180 |
Why?
|
| Nutritional Support | 1 | 2019 | 80 | 0.170 |
Why?
|
| Female | 28 | 2023 | 141928 | 0.170 |
Why?
|
| Drug Substitution | 1 | 2019 | 87 | 0.170 |
Why?
|
| Dietary Carbohydrates | 1 | 2019 | 134 | 0.170 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 527 | 0.170 |
Why?
|
| Thermogenesis | 1 | 2018 | 46 | 0.160 |
Why?
|
| Lipogenesis | 1 | 2018 | 76 | 0.160 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2018 | 97 | 0.160 |
Why?
|
| Tranquilizing Agents | 1 | 2018 | 6 | 0.160 |
Why?
|
| Muscle, Skeletal | 2 | 2018 | 1270 | 0.160 |
Why?
|
| Adipose Tissue, White | 1 | 2018 | 99 | 0.160 |
Why?
|
| Adipose Tissue, Brown | 1 | 2018 | 112 | 0.160 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2018 | 19 | 0.160 |
Why?
|
| Dietary Proteins | 1 | 2019 | 241 | 0.160 |
Why?
|
| Adipogenesis | 1 | 2018 | 105 | 0.150 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 218 | 0.150 |
Why?
|
| Longitudinal Studies | 3 | 2015 | 1945 | 0.150 |
Why?
|
| Physicians | 2 | 2017 | 882 | 0.150 |
Why?
|
| Complementary Therapies | 2 | 2011 | 126 | 0.150 |
Why?
|
| Hormones | 1 | 2018 | 266 | 0.150 |
Why?
|
| Triazoles | 1 | 2021 | 617 | 0.150 |
Why?
|
| Energy Intake | 1 | 2019 | 515 | 0.150 |
Why?
|
| Walking | 1 | 2019 | 277 | 0.150 |
Why?
|
| Morphine | 4 | 2023 | 308 | 0.140 |
Why?
|
| Adult | 20 | 2023 | 77950 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 289 | 0.140 |
Why?
|
| Adipocytes | 1 | 2018 | 305 | 0.140 |
Why?
|
| Goals | 3 | 2023 | 185 | 0.140 |
Why?
|
| Disease Management | 2 | 2019 | 1052 | 0.140 |
Why?
|
| Antipsychotic Agents | 1 | 2020 | 414 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2008 | 2576 | 0.140 |
Why?
|
| Syndrome | 1 | 2019 | 1351 | 0.140 |
Why?
|
| Fatigue | 3 | 2013 | 1239 | 0.130 |
Why?
|
| Disclosure | 1 | 2017 | 181 | 0.130 |
Why?
|
| Hospice Care | 2 | 2017 | 156 | 0.130 |
Why?
|
| Aged | 21 | 2021 | 70117 | 0.130 |
Why?
|
| Hospitalization | 3 | 2023 | 2083 | 0.120 |
Why?
|
| Weight Loss | 3 | 2015 | 627 | 0.120 |
Why?
|
| Retrospective Studies | 14 | 2023 | 37905 | 0.120 |
Why?
|
| Hydrocodone | 1 | 2014 | 55 | 0.120 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 394 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 2594 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 403 | 0.120 |
Why?
|
| Energy Metabolism | 1 | 2019 | 992 | 0.120 |
Why?
|
| Pandemics | 4 | 2023 | 1559 | 0.110 |
Why?
|
| Hydrocortisone | 2 | 2014 | 388 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 1303 | 0.110 |
Why?
|
| Cognition | 1 | 2019 | 968 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 3719 | 0.110 |
Why?
|
| Emotions | 1 | 2017 | 562 | 0.110 |
Why?
|
| Family | 1 | 2017 | 736 | 0.110 |
Why?
|
| Resuscitation Orders | 1 | 2013 | 68 | 0.110 |
Why?
|
| Prospective Studies | 6 | 2023 | 12873 | 0.100 |
Why?
|
| United States | 6 | 2021 | 15433 | 0.100 |
Why?
|
| Anthropometry | 1 | 2012 | 269 | 0.100 |
Why?
|
| Taxoids | 1 | 2015 | 967 | 0.100 |
Why?
|
| Aged, 80 and over | 11 | 2018 | 29902 | 0.100 |
Why?
|
| Bibliometrics | 1 | 2011 | 71 | 0.100 |
Why?
|
| Double-Blind Method | 4 | 2020 | 2588 | 0.100 |
Why?
|
| Cost of Illness | 2 | 2014 | 498 | 0.100 |
Why?
|
| Hematologic Neoplasms | 2 | 2015 | 1870 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2019 | 2803 | 0.090 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2015 | 425 | 0.090 |
Why?
|
| Body Weight | 1 | 2015 | 1293 | 0.090 |
Why?
|
| Survival | 1 | 2010 | 177 | 0.090 |
Why?
|
| Acute Disease | 1 | 2015 | 2422 | 0.090 |
Why?
|
| Publishing | 1 | 2011 | 220 | 0.080 |
Why?
|
| Survival Analysis | 4 | 2015 | 9180 | 0.080 |
Why?
|
| Hormone Replacement Therapy | 2 | 2011 | 205 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2013 | 1450 | 0.080 |
Why?
|
| Decision Making | 2 | 2013 | 1287 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2014 | 6207 | 0.080 |
Why?
|
| Self Report | 1 | 2011 | 756 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2018 | 4078 | 0.080 |
Why?
|
| Adipose Tissue | 1 | 2012 | 769 | 0.070 |
Why?
|
| Progestins | 1 | 2006 | 87 | 0.070 |
Why?
|
| Body Temperature Regulation | 1 | 2006 | 38 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 7222 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2011 | 1171 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2011 | 786 | 0.060 |
Why?
|
| Constipation | 1 | 2006 | 177 | 0.060 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2006 | 126 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 4938 | 0.060 |
Why?
|
| Research Design | 1 | 2011 | 1544 | 0.060 |
Why?
|
| Prognosis | 4 | 2020 | 21713 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 13658 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2011 | 1000 | 0.060 |
Why?
|
| Antidepressive Agents | 1 | 2006 | 332 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 4320 | 0.060 |
Why?
|
| Levorphanol | 1 | 2023 | 14 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 1301 | 0.060 |
Why?
|
| Young Adult | 6 | 2021 | 21445 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 2403 | 0.050 |
Why?
|
| Hydromorphone | 1 | 2022 | 58 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 461 | 0.050 |
Why?
|
| Risk Factors | 1 | 2019 | 17523 | 0.050 |
Why?
|
| Moxibustion | 1 | 2021 | 9 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 8865 | 0.050 |
Why?
|
| Tertiary Healthcare | 1 | 2021 | 44 | 0.050 |
Why?
|
| Urine | 1 | 2020 | 143 | 0.050 |
Why?
|
| Oral Sprays | 1 | 2019 | 8 | 0.040 |
Why?
|
| Administration, Sublingual | 1 | 2019 | 25 | 0.040 |
Why?
|
| Walk Test | 1 | 2019 | 43 | 0.040 |
Why?
|
| Propensity Score | 1 | 2022 | 750 | 0.040 |
Why?
|
| Gastrostomy | 1 | 2021 | 180 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2019 | 191 | 0.040 |
Why?
|
| Physical Exertion | 1 | 2019 | 113 | 0.040 |
Why?
|
| Drug Overdose | 1 | 2019 | 81 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2019 | 209 | 0.040 |
Why?
|
| Texas | 3 | 2015 | 6311 | 0.040 |
Why?
|
| Lorazepam | 1 | 2018 | 40 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 14889 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 717 | 0.040 |
Why?
|
| Mice | 1 | 2018 | 34495 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 718 | 0.040 |
Why?
|
| Inpatients | 1 | 2022 | 678 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 5687 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2022 | 1274 | 0.040 |
Why?
|
| Length of Stay | 1 | 2022 | 1900 | 0.030 |
Why?
|
| Adolescent | 4 | 2023 | 31252 | 0.030 |
Why?
|
| Ibuprofen | 1 | 2014 | 56 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 10035 | 0.030 |
Why?
|
| Thyrotropin | 1 | 2014 | 119 | 0.030 |
Why?
|
| Vitamin B 12 | 1 | 2014 | 73 | 0.030 |
Why?
|
| Treatment Outcome | 4 | 2019 | 32848 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2018 | 554 | 0.030 |
Why?
|
| Animals | 1 | 2018 | 59536 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2014 | 257 | 0.030 |
Why?
|
| Psychometrics | 1 | 2018 | 937 | 0.030 |
Why?
|
| Leptin | 1 | 2015 | 295 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 2992 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2315 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2012 | 129 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 14289 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 524 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2014 | 477 | 0.030 |
Why?
|
| Vitamin D | 1 | 2014 | 261 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 945 | 0.030 |
Why?
|
| Weight Gain | 1 | 2015 | 464 | 0.030 |
Why?
|
| Death | 1 | 2012 | 119 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 1085 | 0.030 |
Why?
|
| Social Support | 1 | 2014 | 560 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 294 | 0.020 |
Why?
|
| Androgens | 1 | 2014 | 511 | 0.020 |
Why?
|
| Symptom Assessment | 1 | 2012 | 267 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2015 | 1038 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2012 | 337 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 589 | 0.020 |
Why?
|
| Quality Control | 1 | 2011 | 457 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 866 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 4971 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 980 | 0.020 |
Why?
|
| Pain, Intractable | 1 | 2011 | 171 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 5767 | 0.020 |
Why?
|
| Pneumonia | 1 | 2015 | 751 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2011 | 289 | 0.020 |
Why?
|
| Caregivers | 1 | 2014 | 677 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2012 | 795 | 0.020 |
Why?
|
| Medical Records | 1 | 2008 | 415 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 4988 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 2055 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 1258 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 2522 | 0.010 |
Why?
|
| Biomarkers | 1 | 2014 | 5047 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2006 | 15694 | 0.010 |
Why?
|
| Algorithms | 1 | 2012 | 3890 | 0.010 |
Why?
|
| Survival Rate | 1 | 2012 | 12221 | 0.010 |
Why?
|
| Child | 1 | 2008 | 29154 | 0.000 |
Why?
|